We evaluated 12-month changes in pancreatic
β-cell function and influencing factors in Japanese subjects with type 2 diabetes (T2DM). Those who showed marked chronic hyperglycemia, who were severely obese, who had progressive hepatic or renal dysfunction, who used incretins, or who used a combination of insulin and an oral hypoglycemic agent (OHA) were excluded. The resulting 205 subjects showing good, stable glycemic control for at least 3 months were included in the final analysis. Pancreatic
β-cell function was assessed by C-peptide reactivity (
ΔCPR) for 6 min in glucagon tests. Clinical parameters were age, gender, diabetes duration, diabetic retinopathy, hypertension, urinary albumin excretion rate (AER), HbA1c, and serum lipids. In a cross-sectional study at the start of observation (baseline), diabetes duration correlated significantly negatively (r=0.357, P<0.001) with
ΔCPR. Stepwise multiple regression analysis of clinical parameters identified diabetes duration as the main predictive independent variable at baseline of
ΔCPR (F=16.951). In a 12-month longitudinal study of all subjects (n=205),
ΔCPR decreased significantly (p<0.001), and when analyzed by treatment type,
ΔCPR decreased significantly in the no-drug treatment group (Group D; n=39; p<0.05) and Group OHA (n=134; p<0.001), but did not change significantly in the insulin group (Group I; n=32). Subanalysis by drug type in Group OHA showed that insulin secretagogue OHAs, particularly sulfonylureas, played a strong role in decreasing
ΔCPR. Our findings suggest that in Japanese subjects with T2DM, changes over the years in insulin secretion by pancreatic
β-cells are influenced by both the natural history of hyperglycemic exposure and the history of treatment modalities undergone.
View full abstract